[Special Stock] Nivec Nears Global Technology Transfer for Peptide New Drug

NaiVec is showing strength. The expectation of a global technology transfer for the world's first tissue regeneration-promoting peptide new drug appears to be influencing the stock price.

As of 10:32 AM on the 8th, NaiVec is trading at 16,520 KRW, up 5.09% from the previous trading day.

Hanyang Securities analyzed NaiVec the day before, stating that the core new drug candidate ‘NP-201’ is about to undergo its first global technology transfer (L/O). They noted that it is a time for re-evaluation. However, they did not provide an investment opinion or target price.

Researcher Oh Byung-yong from Hanyang Securities said, "NaiVec is the top peptide new drug development company in Korea and possesses one of the very few peptide GMP factories in the country." He added, "The core new drug candidate is the peptide new drug NP-201, being developed as a fibrosis treatment, and in addition, they are developing anti-aging treatments using the cell-penetrating peptide platform (NIPEP-TPP), KRAS-targeted anticancer drugs, and more."

Researcher Oh said, "NP-201 is a completely new mechanism of treatment that promotes tissue regeneration to treat fibrosis, unlike existing fibrosis treatments," and "Numerous diseases caused by fibrosis, such as idiopathic pulmonary fibrosis, renal fibrosis, pulmonary arterial hypertension, and inflammatory bowel disease, could be target indications for NP-201."

He analyzed, "NP-201 has been a substance with numerous technology transfer discussions with overseas companies from early development due to its potential in fibrosis treatment," and "Recently, very concrete discussions regarding technology transfer have been conducted with a U.S.-based pharmaceutical company." He emphasized, "We expect the main contract to be signed by June at the latest."

Furthermore, he explained, "The gross profit margin reaches 51.7%, and the dental material business serves as a high-margin cash cow," adding, "There are no concerns about the listing maintenance requirements, which are always an issue in biotech investments."